Cardiovascular diseases (CVDs) and diabetes are the leading causes of death worldwide,
which underlines the urgent necessity to develop new pharmacotherapies. Cinnamon has …

Gene-editing technologies, which include the CRISPR–Cas nucleases 1, 2, 3 and CRISPR
base editors 4, 5, have the potential to permanently modify disease-causing genes in …

Abstract annually in Europe, 4 million people die from cardiovascular diseases, the main
cause of which is atherosclerosis. In order to slow down the development of atherosclerotic …

Background Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin
type 9. Previous studies suggest that inclisiran might provide sustained reductions in low …

Importance Optimal management of patients with asymptomatic severe carotid stenosis is
uncertain, due to advances in medical care and a lack of contemporary data comparing …

Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …

Importance Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent in the US,
with studies indicating substantial rates of nonadherence to and undertreatment with statin …

Importance Sustained reductions in low-density lipoprotein cholesterol (LDL-C) with lipid-
lowering therapies that require frequent dosing are reliant on patient adherence, and poor …

As an important metabolic intermediate of sulfur-containing amino acids in human body,
homocysteine (Hcy) is regarded as an independent risk factor for atherosclerotic …

Current pharmacological treatments of atherosclerosis often target either cholesterol control
or inflammation management, to inhibit atherosclerotic progression, but cannot lead to direct …